University of Salamanca, Instituto de Neurociencias de Castilla y León (INCYL) Laboratorio de Neuroanatomía de los Sistemas Peptidérgicos (Lab. 14) c/ Pintor Fernando Gallego, 1 37007-Salamanca, Spain.
Curr Med Chem. 2013;20(38):4853-8. doi: 10.2174/09298673113206660280.
We summarize the alterations of classical neurotransmitters and neuropeptides and the corresponding subreceptors involved in major depression. Neuronal circuits in the brainstem, hippocampus and hypothalamus are developed, since they can be used to derive a multimodal pharmacotherapy. In this sense, serotonin hypoactivity could occur through a strong presynaptic inhibition of glutaminergic neurons via the subtype 5 of metabotropic glutaminergic receptors, and noradrenaline hypoactivity could be due to an enhanced presynaptic inhibition of GABAergic neurons via GABAB receptors. In the hippocampus, dopamine hypoactivity leads to a decreased positive effect. In clinical trials, the antidepressant effect of drugs interfering with the mentioned subreceptors, for example the triple reuptake inhibitor amitifadine, is being investigated. Moreover, the alterations of neuropeptides, such as corticotropin-releasing hormone, neuropeptide Y and galanin are pointed out. The additional antidepressant effect of analogs, agonists and antagonists of the mentioned neuropeptides should be examined.
我们总结了经典神经递质和神经肽的改变,以及涉及重度抑郁症的相应亚受体。由于可以用于衍生出多模式的药物治疗,因此脑桥、海马体和下丘脑的神经元回路得以发展。在这种意义上,通过代谢型谷氨酸受体 5 亚型对谷氨酸能神经元进行强烈的突触前抑制,可能会发生血清素活性不足,而去甲肾上腺素活性不足可能是由于 GABA 能神经元通过 GABAB 受体的增强的突触前抑制所致。在海马体中,多巴胺活性不足会导致积极作用降低。在临床试验中,正在研究干扰所述亚受体的药物(例如三重再摄取抑制剂阿米替林)的抗抑郁作用。此外,还指出了神经肽(例如促肾上腺皮质激素释放激素、神经肽 Y 和甘丙肽)的改变。应该检查所述神经肽的类似物、激动剂和拮抗剂的额外抗抑郁作用。